Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, and Stribild. The Company’s COVID-19 product is Veklury. The Company’s also provides Epclusa, Harvoni, Vemlidy, and Viread products for liver diseases. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The Company’s other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.

  • Revenue in USD (TTM)27.28bn
  • Net income in USD4.59bn
  • Incorporated1987
  • Employees17.00k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttps://www.gilead.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GILD:NSQ since
MiroBio LtdDeal completed04 Aug 202204 Aug 2022Deal completed33.24%405.00m
Data delayed at least 15 minutes, as of Mar 31 2023 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Moderna Inc19.26bn8.36bn59.23bn3.90k7.693.096.803.0719.9619.9646.3149.670.76254.538.454,939,231.0033.1038.5945.8558.0571.88--43.4148.842.54--0.05310.004.29147.88-31.47--46.94--
Zoetis Inc8.08bn2.11bn77.13bn13.80k37.0317.5229.949.554.494.4917.199.500.56061.156.88585,507.3014.6514.0617.6916.5169.7369.2826.1325.021.6312.660.642224.623.918.773.7814.4621.2124.14
Vertex Pharmaceuticals Incorporated8.93bn3.32bn81.00bn4.80k24.585.8223.349.0712.8212.8234.4754.130.56552.666.931,860,563.0021.0419.9224.8823.8187.9087.7137.2033.694.6672.860.030.0017.9129.1241.8466.04-4.63--
Regeneron Pharmaceuticals Inc12.17bn4.34bn89.83bn11.85k21.493.9719.057.3838.2438.24107.25206.790.44550.71692.141,027,162.0015.8823.1718.2426.9387.1887.6635.6439.794.29254.800.1065---24.2615.70-46.2823.2642.77--
Gilead Sciences, Inc.27.28bn4.59bn103.61bn17.00k22.814.8715.413.803.643.6421.6217.030.41613.625.891,604,765.006.966.608.437.9379.2678.7216.7417.511.156.300.543378.18-0.08790.8836-26.23-14.624.297.02
Amgen, Inc.26.32bn6.55bn129.09bn25.20k19.9535.2612.954.9012.1212.1248.666.860.41691.425.031,044,564.0010.3811.1413.3213.8175.6677.9924.8928.791.107.210.914153.531.322.8711.18-4.107.1111.03
Bristol-Myers Squibb Co46.16bn6.33bn145.78bn34.30k23.484.638.773.162.952.9521.5114.970.44794.545.721,345,744.006.162.807.823.4578.1875.4913.756.981.146.390.5582148.90-0.487217.31-9.5410.141.176.72
Data as of Mar 31 2023. Currency figures normalised to Gilead Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

38.08%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2022106.63m8.50%
BlackRock Fund Advisorsas of 31 Dec 202287.61m6.99%
Capital Research & Management Co. (World Investors)as of 31 Dec 202268.89m5.49%
SSgA Funds Management, Inc.as of 31 Dec 202258.94m4.70%
Capital Research & Management Co. (Global Investors)as of 31 Dec 202254.60m4.35%
Dodge & Coxas of 31 Dec 202235.89m2.86%
Geode Capital Management LLCas of 31 Dec 202223.85m1.90%
BlackRock Advisors (UK) Ltd.as of 31 Dec 202214.18m1.13%
Fidelity Management & Research Co. LLCas of 31 Dec 202214.00m1.12%
Norges Bank Investment Managementas of 31 Dec 202212.99m1.04%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.